Home >> Research Area >>Others>>Glycosylases>> N-Nonyldeoxynojirimycin

N-Nonyldeoxynojirimycin

Glucosidase inhibitor CAS# 81117-35-3

N-Nonyldeoxynojirimycin

Catalog No. BCC7752----Order now to get a substantial discount!

Product Name & Size Price Stock
N-Nonyldeoxynojirimycin: 5mg $115 In Stock
N-Nonyldeoxynojirimycin: 10mg Please Inquire In Stock
N-Nonyldeoxynojirimycin: 20mg Please Inquire Please Inquire
N-Nonyldeoxynojirimycin: 50mg Please Inquire Please Inquire
N-Nonyldeoxynojirimycin: 100mg Please Inquire Please Inquire
N-Nonyldeoxynojirimycin: 200mg Please Inquire Please Inquire
N-Nonyldeoxynojirimycin: 500mg Please Inquire Please Inquire
N-Nonyldeoxynojirimycin: 1000mg Please Inquire Please Inquire
Related Products
  • SU14813

    Catalog No.:BCC1971
    CAS No.:627908-92-3

Quality Control of N-Nonyldeoxynojirimycin

Number of papers citing our products

Chemical structure

N-Nonyldeoxynojirimycin

3D structure

Chemical Properties of N-Nonyldeoxynojirimycin

Cas No. 81117-35-3 SDF Download SDF
PubChem ID 501640 Appearance Powder
Formula C15H31NO4 M.Wt 289.41
Type of Compound N/A Storage Desiccate at -20°C
Synonyms NN-DNJ
Solubility Soluble to 100 mM in DMSO and to 100 mM in ethanol
Chemical Name (2R,3R,4R,5S)-2-(hydroxymethyl)-1-nonylpiperidine-3,4,5-triol
SMILES CCCCCCCCCN1CC(C(C(C1CO)O)O)O
Standard InChIKey FTSCEGKYKXESFF-LXTVHRRPSA-N
Standard InChI InChI=1S/C15H31NO4/c1-2-3-4-5-6-7-8-9-16-10-13(18)15(20)14(19)12(16)11-17/h12-15,17-20H,2-11H2,1H3/t12-,13+,14-,15-/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of N-Nonyldeoxynojirimycin

DescriptionGlucosidase inhibitor (IC50 values are 0.42 and 8.4 μM for acid α-glucosidase and α-1,6-glucosidase respectively). Inhibits liver glycogen breakdown in vivo. Also acts as a chemical chaperone; chaperones β-Glu folding at neutral p.H. allowing the stabilized enzyme to transit from the endoplasmic reticulum to the golgi, enabling proper trafficking to the lysosome.

N-Nonyldeoxynojirimycin Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

N-Nonyldeoxynojirimycin Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of N-Nonyldeoxynojirimycin

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.4553 mL 17.2765 mL 34.5531 mL 69.1061 mL 86.3826 mL
5 mM 0.6911 mL 3.4553 mL 6.9106 mL 13.8212 mL 17.2765 mL
10 mM 0.3455 mL 1.7277 mL 3.4553 mL 6.9106 mL 8.6383 mL
50 mM 0.0691 mL 0.3455 mL 0.6911 mL 1.3821 mL 1.7277 mL
100 mM 0.0346 mL 0.1728 mL 0.3455 mL 0.6911 mL 0.8638 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on N-Nonyldeoxynojirimycin

Inhibition of glycogen breakdown by imino sugars in vitro and in vivo.[Pubmed:14757169]

Biochem Pharmacol. 2004 Feb 15;67(4):697-705.

The imino sugar N-butyldeoxynojirimycin (NB-DNJ) is a glucose analogue which inhibits the glycoprotein N-glycan processing enzymes alpha-glucosidases I and II and the ceramide glucosyltransferase that catalyses the first step of glycosphingolipid biosynthesis. This and other N-alkylated DNJ compounds have the potential to inhibit other glucosidase, including acid alpha-glucosidase and alpha-1,6-glucosidase, enzymes involved in glycogen breakdown. We have investigated the effect of NB-DNJ and N-Nonyldeoxynojirimycin (NN-DNJ) on glycogen catabolism. Both NB-DNJ and NN-DNJ were potent inhibitors of acid alpha-glucosidase and alpha-1,6-glucosidase in vitro. NB-DNJ and NN-DNJ inhibited liver glycogen breakdown in vivo in fasting mice. Inhibition of glycogen catabolism occurred in the cytosol and lysosomes. The liver glycogen breakdown inhibition was only induced at high doses of NB-DNJ, whereas NN-DNJ caused glycogen accumulation at lower doses. The in vivo effect of NB-DNJ on liver glycogen was transient as there was no inhibition of breakdown after 90 days of treatment. The inhibition by NN-DNJ, was more pronounced, reached a plateau at 50 days and then remained unchanged. Increased glycogen was also observed in skeletal muscle in NB-DNJ- and NN-DNJ-treated mice. Since the effects on glycogen metabolism by NB-DNJ are transient and only occur at high concentrations, it is not predicted that glycogen breakdown will be impaired in patients receiving NB-DNJ therapy. NN-DNJ is the prototype of long alkyl chain derivatives of DNJ that are entering pre-clinical development as potential hepatitis B/hepatitis C (HBV/HCV) therapeutics. Depending on the dose of these compounds used, there is the potential for glycogen catabolism to be partially impaired in experimental animals and man.

Cellular effects of deoxynojirimycin analogues: inhibition of N-linked oligosaccharide processing and generation of free glucosylated oligosaccharides.[Pubmed:15128289]

Biochem J. 2004 Aug 1;381(Pt 3):867-75.

In the accompanying paper [Mellor, Neville, Harvey, Platt, Dwek and Butters (2004) Biochem. J. 381, 861-866] we treated HL60 cells with N-alk(en)yl-deoxynojirimycin (DNJ) compounds to inhibit glucosphingolipid (GSL) biosynthesis and identified a number of non-GSL-derived, small, free oligosaccharides (FOS) most likely produced due to inhibition of the oligosaccharide-processing enzymes a-glucosidases I and II. When HL60 cells were treated with concentrations of N-alk(en)ylated DNJ analogues that inhibited GSL biosynthesis completely, N-butyl- and N-nonyl-DNJ inhibited endoplasmic reticulum (ER) glucosidases I and II, but octadecyl-DNJ did not, probably due to the lack of ER lumen access for this novel, long-chain derivative. Glucosidase inhibition resulted in the appearance of free Glc1-3Man structures, which is evidence of Golgi glycoprotein endomannosidase processing of oligosaccharides with retained glucose residues. Additional large FOS was also detected in cells following a 16 h treatment with N-butyl- and N-nonyl-DNJ. When these FOS structures (>30, including >20 species not present in control cells) were characterized by enzyme digests and MALDI-TOF (matrix-assisted laser-desorption ionization-time-of-flight) MS, all were found to be polymannose-type oligosaccharides, of which the majority were glucosylated and had only one reducing terminal GlcNAc (N-acetylglucosamine) residue (FOS-GlcNAc1), demonstrating a cytosolic location. These results support the proposal that the increase in glucosylated FOS results from enzyme-mediated cytosolic cleavage of oligosaccharides from glycoproteins exported from the ER because of misfolding or excessive retention. Importantly, the present study characterizes the cellular properties of DNJs further and demonstrates that side-chain modifications allow selective inhibition of protein and lipid glycosylation pathways. This represents the most detailed characterization of the FOS structures arising from ER a-glucosidase inhibition to date.

Description

N-Nonyldeoxynojirimycin (NN-DNJ) is a potent inhibitor of alpha-glucosidase and alpha-1,6-glucosidase (IC50s, 0.42, 8.4 μM, respectively), inhibits glycogen breakdown.

Keywords:

N-Nonyldeoxynojirimycin,81117-35-3,NN-DNJ,Natural Products,Glycosylases, buy N-Nonyldeoxynojirimycin , N-Nonyldeoxynojirimycin supplier , purchase N-Nonyldeoxynojirimycin , N-Nonyldeoxynojirimycin cost , N-Nonyldeoxynojirimycin manufacturer , order N-Nonyldeoxynojirimycin , high purity N-Nonyldeoxynojirimycin

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: